ARTICLE | Clinical News
Treximet sumatriptan/naproxen regulatory update
February 16, 2015 8:00 AM UTC
Pernix said FDA accepted for review an sNDA for Treximet sumatriptan/naproxen to treat migraine with or without aura in patients ages 12-17. The company expects a decision on the sNDA next quarter. Th...